Jun-Shuai Xue
- Internal Medicine top 10%
-
- Hepatocellular Carcinoma Treatment and Prognosis 9
-
- Cancer Immunotherapy and Biomarkers 7
- Inflammatory Biomarkers in Disease Prognosis 4
- Pancreatic and Hepatic Oncology Research 2
-
- Liver Disease Diagnosis and Treatment 5
-
- Cancer, Lipids, and Metabolism 4
-
- Ferroptosis and cancer prognosis 4
-
- Cancer Mechanisms and Therapy 2
- Cited by
- Internal MedicineHepatologyOncology
- Journals
- SHILAP Revista de lepidopterología (2 papers)Scientific Reports (1 paper)Frontiers in Immunology (2 papers)
- Partner nations
- China
In The Last Decade
Jun-Shuai Xue
21 papers receiving 253 citations
Peers
Comparison fields: 5 of 58
- Internal Medicine 34
- Hepatology 49
- Oncology 138
- Immunology 42
- Epidemiology 62
Countries citing papers authored by Jun-Shuai Xue
This map shows the geographic impact of Jun-Shuai Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun-Shuai Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun-Shuai Xue more than expected).
Fields of papers citing papers by Jun-Shuai Xue
This network shows the impact of papers produced by Jun-Shuai Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun-Shuai Xue. The network helps show where Jun-Shuai Xue may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jun-Shuai Xue, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 7 | |
| 7 | 2023 | 9 | |
| 8 | 2023 | 10 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 6 | |
| 11 | 2023 | 7 | |
| 12 | The Neutrophil/Lymphocyte Ratio is an Independent Predictor of All-Cause Mortality in Patients with Idiopathic Hypereosinophilic Syndrome | 2022 | 3 |
| 13 | 2022 | 27 | |
| 14 | 2022 | 13 | |
| 15 | 2022 | 4 | |
| 16 | 2022 | 8 | |
| 17 | 2022 | 13 | |
| 18 | 2022 | 71 | |
| 19 | 2021 | 43 | |
| 20 | 2021 | 11 |
About Jun-Shuai Xue
Jun-Shuai Xue is a scholar working on Hepatology, Oncology and Cancer Research, having authored 23 papers that have together received 258 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Cancer Immunotherapy and Biomarkers (7 papers), Liver Disease Diagnosis and Treatment (5 papers), Cancer, Lipids, and Metabolism (4 papers), Ferroptosis and cancer prognosis (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers), Cancer Mechanisms and Therapy (2 papers) and Pancreatic and Hepatic Oncology Research (2 papers). The work is most often cited by research in Internal Medicine (34 citations), Hepatology (49 citations) and Oncology (138 citations). Jun-Shuai Xue has collaborated with scholars based in China. Frequent co-authors include Tao Li, Zhao‐Ru Dong, Zi‐Niu Ding, Lun‐Jie Yan, Hui Liu, Zhiqiang Chen, Bao‐Wen Tian, Jian‐Guo Hong, Dongxu Wang and Cheng‐Long Han. Their work appears in journals such as SHILAP Revista de lepidopterología, Scientific Reports and Frontiers in Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.